American Heart Journal
Volume 151, Issue 5 , Pages 969-975 , May 2006

Missed opportunities in the secondary prevention of myocardial infarction: An assessment of the effects of statin underprescribing on mortality

  • Peter C. Austin, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada
    • Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Peter C. Austin, PhD, Institute for Clinical Evaluative Sciences, G1 06, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5.
    • ,
  • Muhammad M. Mamdani, PharmD, MA, MPH

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
    • ,
  • David N. Juurlink, MD, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • Clinical Epidemiology and Health Care Research Program (Sunnybrook and Women's College Site), University of Toronto, Toronto, Canada
    • Division of General Internal Medicine, Sunnybrook and Women's College Health, Sciences Centre and the University of Toronto, Toronto, Ontario, Canada
    • ,
  • David A. Alter, MD, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • Division of Cardiology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
    • ,
  • Jack V. Tu, MD, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada
    • Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • Clinical Epidemiology and Health Care Research Program (Sunnybrook and Women's College Site), University of Toronto, Toronto, Canada
    • Division of General Internal Medicine, Sunnybrook and Women's College Health, Sciences Centre and the University of Toronto, Toronto, Ontario, Canada

Received 18 March 2005 ,Accepted 17 June 2005.

References 

  1. American Heart Association . Heart disease and stroke statistics—2004 update. Dallas (Tex): American Heart Association; 2003;
  2. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423
  3. Pfeffer MA, Sacks FM, Moye LA, et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol. 1995;76:98C–106C
  4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307
  5. Scandanavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  6. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  7. Mamdani MM, Tu JV. Did the major clinical trials of statins affect prescribing behaviour?. CMAJ. 2001;164:1695–1696
  8. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38–44
  9. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864–1870
  10. Tu JV, Donovan LR, Lee DS, et al. Quality of cardiac care in Ontario. Toronto (Ontario): Institute for Clinical Evaluative Sciences; 2004;
  11. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–2587
  12. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516–524
  13. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–763
  14. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–333
  15. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med. 2002;137:693–695
  16. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55
  17. D'Agostino RB. Propensity score methods for bias reduction in the comparison of treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281
  18. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999;159:1793–1802
  19. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690–1691
  20. Austin PC, Tu JV. Bootstrap methods for developing predictive models in cardiovascular research. Am Stat. 2004;58:131–137
  21. Tran CTT, Lee DS, Flintoft VF, et al. CCORT/CCS quality indicators for acute myocardial infarction care. Can J Cardiol. 2003;19:38–45
  22. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462–467
  23. Braunstein JB, Cheng A, Cohn G, et al. Lipid disorders: justification of methods and goals of treatment. Chest. 2001;120:979–988
  24. Genest J, Frohlich J, Fodor G, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003;169:921–924
  25. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553–564
  26. Tomlinson B, Chan P, Lan W. How well tolerated are lipid-lowering drugs?. Drugs Aging. 2001;18:665–683
  27. Bolego C, Baetta R, Bellosta S, et al. Safety considerations for statins. Curr Opin Lipidol. 2002;13:637–644
  28. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  29. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211–4218
  30. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620

 The Institute for Clinical Evaluative Sciences is supported in part by a grant from the Ontario Ministry of Health and Long-term Care. The opinions, results, and conclusions are those of the authors and no endorsement by the Ministry of Health and Long-term Care or by the Institute for Clinical Evaluative Sciences is intended or should be inferred. This research was supported in part by operating grants from the Canadian Institutes of Health Research (CIHR) and the Heart and Stroke Foundation to the Canadian Cardiovascular Outcomes Research Team. Drs Austin, Mamdani, and Juurlink are supported by New Investigator awards from the CIHR. Dr Juurlink is also supported by the University of Toronto Drug Safety Research Group. Dr Alter is supported by a New Investigator award from the CIHR and the Heart and Stroke Foundation. Dr Tu is supported by a Canada Research Chair in Health Services Research.

PII: S0002-8703(05)00651-4

doi: 10.1016/j.ahj.2005.06.034

American Heart Journal
Volume 151, Issue 5 , Pages 969-975 , May 2006

Article Tools

* Image Usage & Resolution